Intellipharmaceutics Cautions Over Financial Future
Company Reports First-Quarter Loss And Looks For New CFO
Executive Summary
Intellipharmaceutics has cautioned over its financial future after the firm’s Aximris XR abuse-deterrent oxycodone hydrochloride extended-release tablets were rejected by an FDA committee earlier this year. The company has reported a net loss of $1.7m for the first quarter of 2020, as it looks for a new chief financial officer.